Research and Product Development
Research and Product Development
An G.B.,POSCO |
Ryu K.M.,POSCO |
Park J.S.,POSCO |
Shin Y.T.,Samsung |
And 6 more authors.
Proceedings of the International Offshore and Polar Engineering Conference | Year: 2011
Recently, there have been the increase of ship size and the development of oil and gas in arctic region. These trends have led to the requirements such as high strength, good toughness at low temperature and good weldability. On the other hand, there has been the key issue of crack arrestability in large size container ship. Steel plates with 80mm thickness were used and two welding processes, which are flux cored arc welding (FCAW) process only and combined welding process (EGW+FCAW), were used to produce full thickness weld joints. The effect of joint design on crack arrestability was investigated to prevent a catastrophic failure along the block joint of hatch side coaming. A brittle crack arrest technique was developed without block joint shift, using an arrest weld in the end of hatch side coaming weld line. Copyright © 2011 by the International Society of Offshore and Polar Engineers (ISOPE).
Kimmerle M.,University of Windsor |
Ferre C.L.,Columbia University |
Kotwica K.A.,Research and Product Development |
Michel G.F.,University of North Carolina at Greensboro
Developmental Psychobiology | Year: 2010
Role-differentiated bimanual manipulation (RDBM) is a complementary movement of both hands that requires differentiation between actions of the hands. Previous research showed that RDBM can be observed in infants as early as 7 months. However, RDBM could be considered a skill only when its frequency, duration, and use is appropriate for the type of manual task, and there is some evidence of intentionality in use. Twenty-four normally developing infants were studied longitudinally at 7, 9, 11, and 13 months to assess the frequency and duration of five clearly different types of RDBM with three "single- part" and three "two-part" toys as they emerge during development. Also, the sequences of actions that lead to RDBM were examined for evidence of "intentionality." The results show that although the each type of RDBM appears early in infancy, RDBM only begins to exhibit the characters of a skill by 13 months. Moreover, the type of toy influences not only the likelihood of eliciting role differentiation, but also the type of RDBM behavior and the organization of the sequence of actions that lead to RDBM. Some useful criteria for defining an infant sensorimotor skill are provided in discussion. © 2009 Wiley Periodicals, Inc.
PubMed | WHO Country Office, The Good and Research and Product Development
Type: | Journal: The Journal of infectious diseases | Year: 2014
Monitoring the quality of supplementary immunization activities (SIAs) is a key tool for polio eradication. Regular monitoring data, however, are often unreliable, showing high coverage levels in virtually all areas, including those with ongoing virus circulation. To address this challenge, lot quality assurance sampling (LQAS) was introduced in 2009 as an additional tool to monitor SIA quality. Now used in 8 countries, LQAS provides a number of programmatic benefits: identifying areas of weak coverage quality with statistical reliability, differentiating areas of varying coverage with greater precision, and allowing for trend analysis of campaign quality. LQAS also accommodates changes to survey format, interpretation thresholds, evaluations of sample size, and data collection through mobile phones to improve timeliness of reporting and allow for visualization of campaign quality. LQAS becomes increasingly important to address remaining gaps in SIA quality and help focus resources on high-risk areas to prevent the continued transmission of wild poliovirus.
Greenland K.,National Institute of Public Health and the Environment |
Greenland K.,Centers for Disease Control and Prevention |
Rondy M.,National Institute of Public Health and the Environment |
Rondy M.,Centers for Disease Control and Prevention |
And 10 more authors.
Tropical Medicine and International Health | Year: 2011
Objectives To evaluate oral poliovirus vaccine (OPV) coverage of the November 2009 round in five Northern Nigeria states with ongoing wild poliovirus transmission using clustered lot quality assurance sampling (CLQAS). Methods We selected four local government areas in each pre-selected state and sampled six clusters of 10 children in each Local Government Area, defined as the lot area. We used three decision thresholds to classify OPV coverage: 75-90%, 55-70% and 35-50%. A full lot was completed, but we also assessed in retrospect the potential time-saving benefits of stopping sampling when a lot had been classified. Results We accepted two local government areas (LGAs) with vaccination coverage above 75%. Of the remaining 18 rejected LGAs, 11 also failed to reach 70% coverage, of which four also failed to reach 50%. The average time taken to complete a lot was 10h. By stopping sampling when a decision was reached, we could have classified lots in 5.3, 7.7 and 7.3h on average at the 90%, 70% and 50% coverage targets, respectively. Conclusions Clustered lot quality assurance sampling was feasible and useful to estimate OPV coverage in Northern Nigeria. The multi-threshold approach provided useful information on the variation of IPD vaccination coverage. CLQAS is a very timely tool, allowing corrective actions to be directly taken in insufficiently covered areas. © 2011 Blackwell Publishing Ltd.
An G.B.,POSCO |
Ryu K.M.,POSCO |
Park J.S.,POSCO |
Park T.D.,Industrial Research Institute |
And 7 more authors.
Proceedings of the International Offshore and Polar Engineering Conference | Year: 2010
The evaluation of the brittle crack arrest toughness value (Kca) and the development of the brittle crack arrest method for the welded joint of shipbuilding steel plate were experimentally conducted. Steel plates with 80mm thickness were used and two welding processes, which are flux cored arc welding (FCAW) process only and combined welding process (EGW+FCAW), were used to produce full thickness weld joints. Temperature gradient ESSO test was performed to measure Kca of the welded joints. To develop the brittle crack arrest method, actual structural specimens were utilized to conduct ESSO test at -10° uniform temperature. According to the experimental results of crack arrestability investigation of thick shipbuilding steel plates, the arrester hole design for the welded joint is very effective to arrest the brittle crack without shifting the block. © 2010 by The International Society of Offshore and Polar Engineers (ISOPE).
News Article | February 15, 2017
Jim DeMaioribus Named VP of Marketing; Christopher Cano Named VP, Business Development; Stephane Levy, MD Named VP of Research & Development U.S. Operations EXTON, PA--(Marketwired - February 14, 2017) - Almirall's Aqua Pharmaceuticals, a specialty dermatology company focusing on acquiring, developing and marketing prescription medical dermatology products in the U.S., has today announced it has hired three key executives. Jim DeMaioribus has been appointed Vice President of Marketing and Christopher Cano has been named Vice President, Business Development, both reporting to Ted White, President & General Manager at Aqua Pharmaceuticals. Stephane Levy, MD will fill the role of Vice President of Research & Development U.S. Operations, reporting to Thomas Eichholtz, Head of Research & Development at Almirall. "Jim, Christopher and Stephane have played an integral role in advancing the pharmaceutical industry in their respective disciplines," said White. "Their proven leadership skills and deep expertise makes them ideally suited to help Aqua Pharmaceuticals build its product portfolio in the U.S." In this role, DeMaioribus will be responsible for developing and implementing marketing strategies and tactics that strengthen the Aqua brand, and help drive profitable growth across the portfolio of Aqua products. Prior to joining Aqua Pharmaceuticals, DeMaioribus was Founder and Managing Director of LSM Marketing, LLC which advised some of the top life science companies on marketing strategies designed to accelerate growth. Before forming LSM Marketing, Jim spent 13 years with Johnson & Johnson where he held a variety of senior marketing and commercial positions across its pharmaceutical and medical device businesses. He currently serves as a Fellow at the Wharton School of the University of Pennsylvania. As Vice President of Business Development, Cano will lead all U.S. business development projects. He will work cross-functionally with the Almirall Global Business Development team, establishing strong relationships with key opinion leaders in order to assess new markets and pursue relevant dermatology opportunities. Cano has a high level of expertise in key therapeutic areas such as dermatology, diabetes care and women's health. Prior to joining Aqua Pharmaceuticals, Cano worked at Duchesnay as Director of Business Development, at Noven Pharmaceuticals as Associate Director of Business Development, and held roles of increasing responsibilities at Nucryst Pharmaceuticals and Barrier Therapeutics. In Dr. Levy's new role, he will be responsible for the leadership and management of Aqua Pharmaceuticals' U.S. Research and Product Development organization including all aspects of project management, clinical development, chemistry, manufacturing & controls, toxicology, regulatory affairs, medical affairs and quality assurance. Overseeing the development of all new drug and device products for the U.S. market, he will lead a team to develop, implement and coordinate product lifecycle infrastructure, ensuring the consistent manufacturing of safe and effective products. Before joining Aqua Pharmaceuticals, Dr. Levy served as Vice President and Medical Unit Head of Immunology & Dermatology at Novartis U.S. Throughout his more than 20 years of experience in in clinical development, he has also held executive roles at Genzyme and Sanofi. Headquartered in West Chester, Pennsylvania, Aqua Pharmaceuticals, an Almirall company, is dedicated to helping patients achieve their goals of healthy skin and a positive self-image. The company has leading branded prescription drugs in four therapeutic categories that include acne, steroid-responsive dermatoses, actinic keratoses and seborrheic dermatitis. For more information, please visit www.aquapharm.com. Almirall is a global company based in Barcelona dedicated to providing valuable medicines and medical devices through its R&D, agreements and alliances. Our work covers the whole of the drug value chain. A consolidated growth allows us to devote our talent and efforts towards specialty areas and particularly to further grow as a leading Dermatology player. We are a specialist company, enabling us to accomplish the purpose of providing our innovative products wherever they are needed. Founded in 1943, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision, and the commitment of its long-standing major shareholders. In 2015, Almirall revenues totalled 769 million euros and, with 1,800 employees, it has become a trusted presence across Europe, as well as in the U.S. For more information, please visit www.almirall.com.
Brown A.E.,Research and Product Development |
Brown A.E.,University of Vermont |
Okayasu H.,Research and Product Development |
Nzioki M.M.,WHO Country Office |
And 5 more authors.
Journal of Infectious Diseases | Year: 2014
Monitoring the quality of supplementary immunization activities (SIAs) is a key tool for polio eradication. Regular monitoring data, however, are often unreliable, showing high coverage levels in virtually all areas, including those with ongoing virus circulation. To address this challenge, lot quality assurance sampling (LQAS) was introduced in 2009 as an additional tool to monitor SIA quality. Now used in 8 countries, LQAS provides a number of programmatic benefits: identifying areas of weak coverage quality with statistical reliability, differentiating areas of varying coverage with greater precision, and allowing for trend analysis of campaign quality. LQAS also accommodates changes to survey format, interpretation thresholds, evaluations of sample size, and data collection through mobile phones to improve timeliness of reporting and allow for visualization of campaign quality. LQAS becomes increasingly important to address remaining gaps in SIA quality and help focus resources on high-risk areas to prevent the continued transmission of wild poliovirus. © Crown copyright 2014.
News Article | November 17, 2016
Nellson Nutraceutical, the leading full-service nutrition bar and powder provider in North America, announced a realignment of their organization naming Jean Filion as Chief Operating Officer and Bart Child as Senior Vice President of Commercial Development. Jamie Better, Nellson’s Chief Executive Officer, stated, “Over the past two years we have aggressively transformed Nellson, tripling it in size through the acquisitions of MultiBar, as well as the bar and powder operations of NBTY. This reorganization furthers the integration of those strategic initiatives to better serve the needs of our customers by streamlining communication, reducing functional and geographic barriers, and strengthening critical business processes. As President of Nellson Canada, Jean Filion successfully integrated the former MultiBar business with Nellson’s Canadian operations. With the additional role of Chief Operating Officer, Jean now will oversee all Nellson operations and will harmonize our business processes across our West Coast and Canadian footprint.” Better continued, “Bart Child will take on a new role as Senior Vice President of Commercial Development. This functional group now will include Research and Product Development in addition to Bart’s previous responsibilities for Sales and Marketing. This change will allow us to sharpen our customer focus by tightening product development efforts, accelerating Nellson’s time-to-market for new products, and enhancing collaboration in providing turnkey solutions for our customers.” “This realignment, along with our recently announced plan to build a new state-of-the-art bar manufacturing facility in Ontario, California to meet the growing demands of our customers, reflect Nellson’s determination to be the co-manufacturing partner of choice for leading brands in the nutritional bar and functional powder marketplace,” stated Better.